No Detail Found!

Post Chikungunya Arthritis: A Real Diagnostic and Therapeutic Challenge

Author(s)
Muhammad Ishaq Ghauri Jinnah Medical College Hospital, Department of Internal Medicine, Karachi, Pakistan
Muhammad Shariq Mukarram Jinnah Medical College Hospital, Department of Internal Medicine, Karachi, Pakistan
Ashok Kumar Jinnah Medical College Hospital, Department of Internal Medicine, Karachi, Pakistan
Amir Riaz Jinnah Medical College Hospital, Department of Internal Medicine, Karachi, Pakistan
Urooj Riaz Jinnah Medical College Hospital, Department of Internal Medicine, Karachi, Pakistan
Mashood Iqbal Jinnah Medical College Hospital, Department of Internal Medicine, Karachi, Pakistan
Abstract
Objective: To evaluate the response of disease modifying anti rheumatic drugs (DMARDs) on patients diagnosed with post chikungunya inflammatory arthritis attending outpatient department of Rheumatology, Jinnah Medical College Hospital, Karachi, Pakistan. Methods: This prospective case series study was conducted at Rheumatology clinic of Jinnah Medical College Hospital in Karachi, Pakistan from January - June 2017 after a serious Chikungunya outbreak in November 2016. All patients diagnosed with Chikungunya viral fever who had joint pain refractory to non-steroidal anti-inflammatory drugs (NSAIDs) were evaluated. All eligible patients were given a trial of DMARDs along with systemic steroids (tapering) for 6 months. Clinical response and inflammatory burden were evaluated using the Disease Activity Score (DAS 28). Results: Of 112 patients, more than half the population, 65/112 (58%) was in acute flare of disease at the beginning of study and interestingly not a single patient had high disease activity (DAS >5.1) at the end of 6 months. Patients who went into disease remission were able to lead a pain free life, while those with a relatively higher DAS28 were still struggling with the disease. The overall response to the therapy was eloquent. None of the patient remained in active flair by the end of 6 months. The mean DAS significantly decline at 6 months as compared to the baseline DAS (2.79 ±0.89 vs. 4.96 ±1.11 respectively, p-value <0.001) Conclusion: Chikungunya virus can lead to symmetrical inflammatory arthritis that phenotypically mimics Rheumatoid arthritis but is not primarily Rheumatoid arthritis. The pathogenesis of the disease process is still under study. It is concluded that there is a significant role of DMARDs in treating arthritis associated with CHIKV which can be used in controlling the inflammation and disease progression.
Publication Details
Page(s) 22-26
DOI DOI not available
Published Journal: Journal of Dow University of Health Sciences, Volume: 14, Issue: 1, Year: 2020

Request the full text from PASTIC

Keywords
Non-steroidal Antiinflammatory, Chikungunya (CHIK), Arthritis, Disease modifying anti rheumatic drugs (DMARDs)
0

Citations

0

Downloads

47

Views